Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progression-free survival (PFS) CARTITUDE-4 is the first randomized Phase 3 study investigating the efficacy of a cell therapy as early as after first relapse in multiple myeloma RARITAN, N.J., June 6, 2023 /PRNewswire/ — The Janssen Pharmaceutical … Read more

CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

At 16-months median follow-up, CARVYKTI® significantly improved progression-free survival compared to two standard treatments1 Data presented at the 2023 ASCO and EHA Annual Meetings and published in The New England Journal of Medicine CHICAGO, June 5, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 … Read more